<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0003">
 <label>Table 3</label>
 <caption>
  <p>PREVENT-HD trial outcomes</p>
 </caption>
 <alt-text id="alt0007">Table III</alt-text>
 <table frame="hsides" rules="groups">
  <tbody>
   <tr>
    <td valign="top">
     <bold>Primary efficacy outcome</bold>
    </td>
   </tr>
   <tr>
    <td valign="top">Time to first occurrence of a composite endpoint of symptomatic venous thromboembolism (VTE), myocardial infarction (MI), ischemic stroke, acute limb ischemia, noncentral nervous system (non-CNS) systemic embolization, all-cause hospitalization, and all-cause mortality up to Day 35</td>
   </tr>
   <tr>
    <td valign="top">
     <bold>Secondary efficacy outcomes</bold>
    </td>
   </tr>
   <tr>
    <td valign="top">• Time to first occurrence of a composite end point of symptomatic VTE, MI, ischemic stroke, acute limb ischemia, non-CNS systemic embolization, and all-cause mortality up to Day 35</td>
   </tr>
   <tr>
    <td valign="top">• Time to first occurrence of all-cause hospitalization up to day 35</td>
   </tr>
   <tr>
    <td valign="top">• Time to first occurrence of symptomatic VTE up to day 35</td>
   </tr>
   <tr>
    <td valign="top">• Time to first occurrence of an emergency room (ER) visit up to Day 35</td>
   </tr>
   <tr>
    <td valign="top">• Time to first occurrence of symptomatic VTE, MI, ischemic stroke, acute limb ischemia, non-CNS systemic embolization, and all-cause hospitalization up to day 35</td>
   </tr>
   <tr>
    <td valign="top">• Incidence of participants who are hospitalized or dead from any cause on day 35</td>
   </tr>
   <tr>
    <td valign="top">• Time to all-cause mortality up to day 35</td>
   </tr>
   <tr>
    <td valign="top">
     <bold>Exploratory efficacy outcomes</bold>
    </td>
   </tr>
   <tr>
    <td valign="top">• World Health Organization [WHO] Research and Development Blueprint: Novel Coronavirus Scale for Clinical Improvement over time</td>
   </tr>
   <tr>
    <td valign="top">• Time to first occurrence of a component event of the primary efficacy end point (MI, ischemic stroke, acute limb ischemia, and non-CNS systemic embolization) up to day 35</td>
   </tr>
   <tr>
    <td valign="top">• The incidence of participants achieving an oxygen saturation (O2
     <sub>sat</sub>) below 92% on room air at rest or with ambulation up to day 35
    </td>
   </tr>
   <tr>
    <td valign="top">• The incidence of participants achieving an O2
     <sub>sat</sub> below 88% on room air at rest or with ambulation up to day 35
    </td>
   </tr>
   <tr>
    <td valign="top">• The incidence of participants requiring supplemental oxygen up to day 35</td>
   </tr>
   <tr>
    <td valign="top">• Time to first occurrence of the use of noninvasive ventilation or high-flow oxygen (WHO 5), Intubation and mechanical ventilation (WHO 6), or ventilation and additional organ support (vasopressors, renal replacement therapy [RRT], extracorporeal membrane oxygenation [ECMO]; WHO 7) or all-cause mortality (WHO 8) up to day 35</td>
   </tr>
   <tr>
    <td valign="top">• The incidence of participants requiring dialysis or having an estimated glomerular filtration rate (eGFR) &lt;15 mL/min/1.73 m
     <sup>2</sup> on 2 measurements more than 24 hours apart up to day 35
    </td>
   </tr>
   <tr>
    <td valign="top">• Time to first occurrence of disseminated intravascular coagulation (DIC) up to day 35</td>
   </tr>
   <tr>
    <td valign="top">• Time to first occurrence of acute respiratory distress syndrome (ARDS) up to day 35</td>
   </tr>
   <tr>
    <td valign="top">• The incidence of occurrence of COVID digit up to day 35</td>
   </tr>
   <tr>
    <td valign="top">• Medical Resource Utilization data over time</td>
   </tr>
   <tr>
    <td valign="top">
     <bold>Primary safety outcome</bold>
    </td>
   </tr>
   <tr>
    <td valign="top">Time to first occurrence of International Society on Thrombosis and Hemostasis (ISTH) critical site and fatal bleeding on treatment (+2 days)</td>
   </tr>
   <tr>
    <td valign="top">
     <bold>Secondary safety outcomes</bold>
    </td>
   </tr>
   <tr>
    <td valign="top">• Time to first occurrence of ISTH major bleeding on treatment (+2 days)</td>
   </tr>
   <tr>
    <td valign="top">• Time to first occurrence of nonmajor clinically relevant bleeding on treatment (+2 days)</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
